trial

Study on Communication Comprehension in the Schizophrenic Spectrum

NCTId NCT03225027
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 59 (actual)
Sponsored by Hôpital NOVO
Primary completion 2019-05-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
59 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2016-11-15
Primary completion
2019-05-27
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Emotional judgment taskPost-experimental questionnaireRecognition taskDetection taskCAPE-42Trait Emotional Intelligence QuestionnairePositive And Negative Syndrome ScaleMini International Neuropsychiatric Interview

Sponsors

Hôpital NOVOLead Sponsor

Investigators

2
Mouna TRABELSI, MDPrincipal Investigator
Virginie BEAUCOUSIN, PhDStudy Chair

Sites

1 total
Cergy-Pontoise, France

Facts & assertions

4 sourced
Enrollment
59
Phase
NA
Primary Completion Date
2019-05-27
Status
COMPLETED
relationships
The graph out of here
drug
Emotional judgment task
drug
Post-experimental questionnaire
drug
Recognition task
drug
Detection task
drug
CAPE-42
drug
Trait Emotional Intelligence Questionnaire
drug
Positive And Negative Syndrome Scale
drug
Mini International Neuropsychiatric Interview
drug
lead_sponsor
Hôpital NOVO
company
indication
Schizophrenia
indication
Schizophrenia Simple
indication
investigator
Mouna TRABELSI, MD
person
Virginie BEAUCOUSIN, PhD
person